Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRI Markers for Galantamine in Alzheimer's Disease
NCT00523666Phase 4Unknown
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Sep 2006
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Alzheimer's disease (AD) comparing Galantamine with Placebo -> Galantamine (2 arms). Primary endpoints: Cortical and subcortical volumetric markers at 12 months and Diffusion tensor imaging markers at 12 months. Status: unknown.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00523666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00523666.